Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines.

Binding of the P-, L-, and E-selectins to sialyl Lewis(x) (sLe(x)) retards circulating leukocytes, thereby facilitating their attachment to the blood vessels of allografts. Whether the selectin inhibitor bimosiamose (BIMO; C(46)H(54)O(16) . 0.25 H(2)O [867.4 molecular weight]) inhibits the rejection process of kidney allografts in a rat model was examined. Rat recipients acutely rejected kidney allografts at a mean survival time of 8.8 +/- 0.75 d. An intravenous 7-d infusion by osmotic pump of 2.5, 5, 10, or 20 mg/kg BIMO extended kidney allograft survival to 11.5 +/- 2.2 d (P < 0.03), 25.4 +/- 11.4 d (P < 0.006), 37.4 +/- 13.6 d (P < 0.001), and 39.8 +/- 34.5 d (P < 0.01), respectively. Combination of BIMO with cyclosporine produced synergistic interactions, as documented by the combination index (CI) values of 0.34 to 0.43 (CI <1 is synergistic; CI = 1 is additive; and CI >1 is antagonistic). Similarly, BIMO interacted synergistically with sirolimus (CI = 0.64) and FTY720 (CI = 0.22). While the mechanism of immunosuppression was being analyzed, decreased infiltration of CD4(+), CD8(+), and macrophages on day 7 after grafting was observed. Multiple cytokines were also expressed, including IL-1alpha, IL-1beta, IL-2, IL-4, IL-6, IL-10, IL-12, IL-18, TNF-alpha, and IFN-gamma in kidney allografts on days 3, 5, and 7 after grafting, as measured by a ribonuclease protection assay. Furthermore, at similar time points, BIMO treatment reduced intragraft expression of P-selectin glycoprotein ligand-1, CX(3)CL1, CCL19, CCL20, and CCL2. Thus, BIMO blocks allograft rejection by reduction of intragraft expression of cytokines and chemokines.

[1]  P. Scott,et al.  Th1 Cell-Mediated Resistance to Cutaneous Infection with Leishmania major Is Independent of P- and E-Selectins 1 , 2003, The Journal of Immunology.

[2]  N. Elshourbagy,et al.  Characterization of CC‐chemokine receptor 7 expression on murine T cells in lymphoid tissues , 2003, Immunology.

[3]  Hae-Ock Lee,et al.  P-Selectin and P-Selectin Glycoprotein Ligand 1 Are Major Determinants for Th1 Cell Recruitment to Nonlymphoid Effector Sites in the Intestinal Lamina Propria , 2003, The Journal of experimental medicine.

[4]  S. Fisher,et al.  The Human Placenta Remodels the Uterus by Using a Combination of Molecules That Govern Vasculogenesis or Leukocyte Extravasation , 2003, Annals of the New York Academy of Sciences.

[5]  Shile Huang,et al.  Rapamycins: Mechanisms of Action and Cellular Resistance , 2003, Cancer biology & therapy.

[6]  H. Rabb,et al.  The role of adhesion molecules and T cells in ischemic renal injury , 2003, Current opinion in nephrology and hypertension.

[7]  R. Kannagi.  Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. , 2002, Current opinion in structural biology.

[8]  F. Gao,et al.  FTY720 Pretreatment Reduces Warm Hepatic Ischemia Reperfusion Injury Through Inhibition of T‐Lymphocyte Infiltration , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  D. J. Goetz,et al.  The N-terminal peptide of PSGL-1 can mediate adhesion to trauma-activated endothelium via P-selectin in vivo. , 2002, Blood.

[10]  D. Huszar,et al.  Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury , 2002, Journal of Neuroimmunology.

[11]  W. Hancock,et al.  Chemokines and transplant immunobiology. , 2002, Journal of the American Society of Nephrology : JASN.

[12]  S. Hagl,et al.  Poly(ADP-Ribose) Polymerase Inhibition Reduces Reperfusion Injury After Heart Transplantation , 2002, Circulation research.

[13]  B. Kasiske,et al.  Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. , 2001, Kidney international.

[14]  C. Ballantyne,et al.  Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. , 2001, Transplantation.

[15]  K. Dobashi,et al.  A highly selective inhibitor of Rho-associated coiled-coil forming protein kinase, Y-27632, prolongs cardiac allograft survival of the BALB/c-to-C3H/He mouse model. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  D. Salant,et al.  Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection , 2001 .

[17]  A. Luster,et al.  Donor-Derived Ip-10 Initiates Development of Acute Allograft Rejection , 2001, The Journal of experimental medicine.

[18]  D. Patel,et al.  A Role for Fractalkine and Its Receptor (CX3CR1) in Cardiac Allograft Rejection1 , 2000, The Journal of Immunology.

[19]  W. Hancock,et al.  Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection , 2000, The Journal of experimental medicine.

[20]  L. Toledo-Pereyra,et al.  Multiple selectin blockade with a small molecule inhibitor downregulates liver chemokine expression and neutrophil infiltration after hemorrhagic shock. , 2000, The Journal of trauma.

[21]  R. Dixon,et al.  Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. , 2000, The Journal of allergy and clinical immunology.

[22]  J. Cyster,et al.  Chemokines and cell migration in secondary lymphoid organs. , 1999, Science.

[23]  M. Bowyer,et al.  Attenuation of renal ischemia-reperfusion injury with selectin inhibition in a rabbit model. , 1999, American journal of surgery.

[24]  W. Hancock,et al.  NEW MODEL OF COLD ISCHEMIA/REPERFUSION INJURY: CCR1 KNOCKOUT MICE ARE PROTECTED AGAINST RENAL INJURY. , 1999 .

[25]  H. Broxmeyer,et al.  Chemokines: signal lamps for trafficking of T and B cells for development and effector function , 1999, Journal of leukocyte biology.

[26]  R. Bronson,et al.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Stepkowski,et al.  Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus. , 1998, Transplantation.

[28]  K. Moore,et al.  Structure and function of P-selectin glycoprotein ligand-1. , 1998, Leukemia & lymphoma.

[29]  R. Dixon,et al.  Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4-(2-alpha-D- mannopyranosyloxy)phenyl]hexane (TBC1269). , 1998, Journal of medicinal chemistry.

[30]  W. von Scheidt,et al.  Cardiac allograft vasculopathy: a review. , 1997, Circulation.

[31]  Tracey Jb,et al.  Characterization of the P-selectin ligand on human hematopoietic progenitors. , 1996 .

[32]  L Timmermann,et al.  The mechanism of action of cyclosporin A and FK506. , 1996, Clinical immunology and immunopathology.

[33]  Richard O Hynes,et al.  Susceptibility to Infection and Altered Hematopoiesis in Mice Deficient in Both P- and E-Selectins , 1996, Cell.

[34]  N. Perico,et al.  Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. , 1995, Journal of the American Society of Nephrology : JASN.

[35]  E. Butcher.  Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity , 1991, Cell.

[36]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[37]  C. Martínez-A,et al.  Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. , 2001, Annual review of immunology.

[38]  T. Junt,et al.  Receptor 7–dependent and –independent Pathways for Lymphocyte Homing: Modulation by FTY720 , 2001 .

[39]  D. Salant,et al.  Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. , 2001, The Journal of clinical investigation.

[40]  W. Hancock,et al.  Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. , 2000, The Journal of clinical investigation.

[41]  D. Vestweber,et al.  Mechanisms that regulate the function of the selectins and their ligands. , 1999, Physiological reviews.

[42]  B Dewald,et al.  Human chemokines: an update. , 1997, Annual review of immunology.

[43]  H. Rinder,et al.  Characterization of the P-selectin ligand on human hematopoietic progenitors. , 1996, Experimental hematology.

[44]  T. Springer,et al.  Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. , 1995, Annual review of physiology.

[45]  M P Bevilacqua,et al.  Endothelial-leukocyte adhesion molecules. , 1993, Annual review of immunology.

[46]  S. Schreiber,et al.  The mechanism of action of cyclosporin A and FK506. , 1992, Immunology today.

[47]  C. V. van Buren,et al.  The impact of steady-state cyclosporine concentrations on renal allograft outcome. , 1990, Transplantation.

[48]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.